{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:17:22Z","timestamp":1791029842900,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd002994","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2005,4,20]],"date-time":"2005-04-20T00:00:00Z","timestamp":1113955200000}}],"reference-count":108,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002994.pub2","type":"journal-article","created":{"date-parts":[[2005,4,22]],"date-time":"2005-04-22T14:35:41Z","timestamp":1114180541000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prostacyclin for pulmonary hypertension in adults"],"prefix":"10.1002","author":[{"given":"N Shanthi","family":"Paramothayan","sequence":"first","affiliation":[{"name":"St Helier Hospital; Sutton Surrey UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby J","family":"Lasserson","sequence":"additional","affiliation":[{"name":"St George's, University of London; Community Health Sciences; Cranmer Terrace Tooting London UK SW17 ORE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol","family":"Wells","sequence":"additional","affiliation":[{"name":"Royal Brompton Hospital; Respiratory Medicine; Sydney Street London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Haydn","family":"Walters","sequence":"additional","affiliation":[{"name":"University of Tasmania Medical School; Discipline of Medicine; 43, Collins Street PO BOX 252-34 Hobart Tasmania Australia 7001"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,4,20]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD002994.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease","volume":"132","author":"Badesch","year":"2000","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002994.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Annals of Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD002994.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"issue":"9","key":"10.1002\/14651858.CD002994.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized,double-blind, placebo-controlled trial","volume":"39","author":"Gali\u00e8","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD002994.pub2-BIB0005|cit5","first-page":"A411","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue in patients with pulmonary arterial hypertension: a randomised, double-blind, placebo-controlled trial","volume":"165","author":"Simmoneau","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002994.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analogue for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD002994.pub2-BIB0007|cit7","first-page":"A411","article-title":"Positive outcome of the aerosolized iloprost randomised trial for treatment of severe pulmonary hypertension (AIR study) [Abstract]","volume":"165","author":"Olschewski","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002994.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled Iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"New Egland Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD002994.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (Epoprostenol)","volume":"112","author":"Rubin","year":"1990","journal-title":"Annals of Internal Medicine"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD002994.pub2-BIB0010|cit10","first-page":"A570","article-title":"Improvement in exercise tolerance with treprostinil is dose related for pulmonary arterial hypertension","volume":"165","author":"McLaughlin","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002994.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.126.2.420","article-title":"Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with collagen vascular disease","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD002994.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension","volume":"165","author":"Simonneau","year":"2002","journal-title":"American Journal of Respiratory Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002994.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0002-9343(05)80004-X","article-title":"Failure of vasodilator infusion to alter pulmonary diffusing capacity in systemic sclerosis","volume":"90","author":"Thurm","year":"1991","journal-title":"The American Journal of Medicine"},{"issue":"1139","key":"10.1002\/14651858.CD002994.pub2-BIB0014|cit14","first-page":"80","article-title":"Treprostinil (Remodulin) for pulmonary arterial hypertension","volume":"44","author":"Anonymous","year":"2002","journal-title":"Medical Letter on Drugs & Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD002994.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0011-393X(02)80029-7","article-title":"Complete results of the first randomised placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension","volume":"63","author":"Badesch","year":"2002","journal-title":"Current Therapeutic Research"},{"issue":"6","key":"10.1002\/14651858.CD002994.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-121-6-199409150-00003","article-title":"Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin","volume":"121","author":"Barst","year":"1994","journal-title":"Annals of Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD002994.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/rheumatology\/35.11.1187","article-title":"Intermittent Iloprost infusion therapy of pulmonary hypertension in scleroderma - a pilot study","volume":"35","author":"Bartosik","year":"1996","journal-title":"British Journal of Rheumatology"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0018|cit18","first-page":"255","article-title":"Continuous intravenous epoprostenol in pulmonary hypertension","volume":"4","author":"Bendayan","year":"2002","journal-title":"Israeli Medical Journal"},{"issue":"Suppl 19","key":"10.1002\/14651858.CD002994.pub2-BIB0019|cit19","first-page":"195s","article-title":"Influence of long term continous infusion of epoprostenol on survival in patients wiht primary pulmonary hypertension: the French experience","volume":"8","author":"Brenot","year":"1995","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD002994.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1183\/09031936.04.00020004","article-title":"Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension","volume":"23","author":"Bresser","year":"2004","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD002994.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1358\/dot.2004.40.3.820086","article-title":"Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension","volume":"40","author":"Budev","year":"2004","journal-title":"Drugs of Today"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1164\/ajrccm.165.3.2106033","article-title":"Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension","volume":"165","author":"Castelain","year":"2002","journal-title":"American Journal of Respiratory Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002994.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0300-8932(03)76889-4","article-title":"Treatment of HIV-associated pulmonary hypertension with treprostinil","volume":"56","author":"Cea-Calvo","year":"2003","journal-title":"Revista Espanola De Cardiologia"},{"issue":"11","key":"10.1002\/14651858.CD002994.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1445-5994.2005.00934.x","article-title":"Combining treprostinil and sildenafil in the treatment of pulmonary hypertension","volume":"35","author":"Chua","year":"2005","journal-title":"Internal Medicine Journal"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD002994.pub2-BIB0025|cit25","first-page":"A572","article-title":"Comparison of the acute hemodinamics effects of oxygen 100% and inhaled iloprost in severe and refractory pulmonary hypertension","volume":"165","author":"C\u00e1neva","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002994.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0041-1345(03)00750-4","article-title":"Primary pulmonary hypertension: survival benefits of therapy with prostacyclin analogs and transplantation","volume":"35","author":"Dandel","year":"2003","journal-title":"Transplantation Proceedings"},{"issue":"10","key":"10.1002\/14651858.CD002994.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/art.1780371018","article-title":"Long-term Iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue disease","volume":"37","author":"Mata","year":"1994","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD002994.pub2-BIB0028|cit28","first-page":"66","article-title":"Iloprost in intensive medicine","author":"Ewert","year":"2001","journal-title":"Journal f\u00fcr An\u00e4sthesie"},{"issue":"2","key":"10.1002\/14651858.CD002994.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF03256644","article-title":"Prostanoids for pulmonary arterial hypertension","volume":"2","author":"Galie","year":"2003","journal-title":"American Journal of Respiratory Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002994.pub2-BIB0030|cit30","first-page":"226","article-title":"Intraoperative inhalation of nebulized iloprost during OLT reduces pulmonary hypertension after reperfusion","volume":"9","author":"Gerlach","year":"2002","journal-title":"Journal Fur Anasthesie Und Intensivbehandlung"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1183\/09031936.01.17100140","article-title":"Ultrasonic versus jet nebulisation of iloprost in severe pulmonary hypertension","volume":"17","author":"Gessler","year":"2001","journal-title":"European Respiratory Journal"},{"issue":"7","key":"10.1002\/14651858.CD002994.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-136-7-200204020-00008","article-title":"Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension","volume":"136","author":"Ghofrani","year":"2002","journal-title":"Annals of Internal Medicine"},{"issue":"13","key":"10.1002\/14651858.CD002994.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002994.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1067\/mtc.2003.107","article-title":"Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery","volume":"125","author":"Hache","year":"2003","journal-title":"Journal of Thoracic & Cardiovascular Surgery"},{"issue":"8","key":"10.1002\/14651858.CD002994.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0002-9149(03)00991-3","article-title":"Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease","volume":"92","author":"Hallioglu","year":"2003","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD002994.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/hrt.79.2.175","article-title":"Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost","volume":"79","author":"Higenbottam","year":"1998","journal-title":"Heart"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09031936.01.17100060","article-title":"Trials of inhaled Iloprost and other new vasodilating prostaglandins","volume":"17","author":"Higgenbottam","year":"2001","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD002994.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1378\/chest.124.6.2087","article-title":"Treatment of pulmonary arterial hypertension: a preliminary decision analysis","volume":"124","author":"Highland","year":"2003","journal-title":"Chest"},{"issue":"25","key":"10.1002\/14651858.CD002994.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJM200006223422503","article-title":"Long term tratment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue","volume":"342","author":"Hoeper","year":"2000","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1055\/s-2001-10443","article-title":"Long-term treatment of primary pulmonary hypertension with Iloprost","volume":"55","author":"Hoeper","year":"2001","journal-title":"Pneumologie"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1183\/09031936.02.01512001","article-title":"Pulmonary hypertension in collagen vascular disease","volume":"19","author":"Hoeper","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1183\/09031936.99.13613579","article-title":"Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study","volume":"13","author":"Humbert","year":"1999","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0043|cit43","unstructured":"Humbert M Barst RJ Robbins IM Channick R Manes A Safety & efficacy of bosentan combined with epoprostenol in patients with severe pulmonary arterial hypertension American Thoracic Society 99th International Conference 2003"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/hrt.57.3.270","article-title":"Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin)","volume":"57","author":"Jones","year":"1987","journal-title":"British Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD002994.pub2-BIB0045|cit45","first-page":"41","article-title":"The use of inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension after pulmonary thromboendarterectomy - a randomized double-blind study","volume":"9","author":"Kramm","year":"2002","journal-title":"Journal f\u00fcr Anasthesie und Intensivbehandlung"},{"issue":"3","key":"10.1002\/14651858.CD002994.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0022-5223(03)00704-9","article-title":"Intraoperative inhalation of the long-acting prostacyclin analog iloprost for pulmonary hypertension","volume":"126","author":"Langer","year":"2003","journal-title":"Journal of Thoracic & Cardiovascular Surgery"},{"issue":"5","key":"10.1002\/14651858.CD002994.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1067\/mhj.2002.121806","article-title":"Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension","volume":"143","author":"Langleben","year":"2002","journal-title":"American Heart Journal"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD002994.pub2-BIB0048|cit48","first-page":"A572","article-title":"Acute hemodynamics effects of inhaled oxygen, nitric oxide and iloprost in patients with severe pulmonary hypertension","volume":"165","author":"Leuchte","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002994.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1056\/NEJM199801293380501","article-title":"Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmoanry hypertension","volume":"338","author":"McLaughlin","year":"1998","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002994.pub2-BIB0050|cit50","first-page":"160s","article-title":"A randomsed, double-blind, placebo-controlled study of iloprost inhalation as add-on therapy to Bosentan in pulmonary arterial hypertensions (PAH)","volume":"128","author":"McLaughlin","year":"2005","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD002994.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/1529-0131(199803)41:3<466::AID-ART13>3.0.CO;2-O","article-title":"The acute effects of prostacyclin on pulmonary haemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis","volume":"41","author":"Menon","year":"1998","journal-title":"Arthritis and rheumatism"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/oxfordjournals.eurheartj.a015478","article-title":"An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension","volume":"18","author":"Mikhail","year":"1997","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD002994.pub2-BIB0053|cit53","first-page":"330","article-title":"Management of primary pulmonary hypertension","volume":"9","author":"Mikhail","year":"2002","journal-title":"The British Journal of Cardiology"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/heart.87.4.340","article-title":"Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension","volume":"87","author":"Nagaya","year":"2002","journal-title":"Heart"},{"issue":"3","key":"10.1002\/14651858.CD002994.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/01.CIR.0000109493.05849.14","article-title":"Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension","volume":"109","author":"Nagaya","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD002994.pub2-BIB0056|cit56","first-page":"263","article-title":"Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension","volume":"38","author":"Nakayama","year":"2001","journal-title":"Journal of Cardiology"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0057|cit57","first-page":"73","article-title":"Short-term effect of continuous intravenous prostacyclin (Epoprostenol) in patients with primary pulmonary hypertension","volume":"3","author":"Okano","year":"1996","journal-title":"Medical Book Information"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-124-9-199605010-00006","article-title":"Aerosolized prostacyclin and iloprost in severe pulmonary hypertension","volume":"124","author":"Olschewski","year":"1996","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/ajrccm.160.2.9810008","article-title":"Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis","volume":"160","author":"Olschewski","year":"1999","journal-title":"American Journal Critical Care Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002994.pub2-BIB0060|cit60","first-page":"A595","article-title":"Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis","volume":"157","author":"Olschewski","year":"1998","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-132-6-200003210-00003","article-title":"Inhaled iloprost to treat severe pulmonary hypertension","volume":"132","author":"Olschewski","year":"2000","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002994.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1378\/chest.124.4.1294","article-title":"Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension","volume":"124","author":"Olschewski","year":"2003","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD002994.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pharmthera.2004.01.003","article-title":"Prostacyclin and its analogues in the treatment of pulmonary hypertension","volume":"102","author":"Olschewski","year":"2004","journal-title":"Pharmacology & Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD002994.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1253\/circj.67.375","article-title":"Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension","volume":"67","author":"Ono","year":"2003","journal-title":"Circulation Journal"},{"issue":"5","key":"10.1002\/14651858.CD002994.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1378\/chest.123.5.1583","article-title":"Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction","volume":"123","author":"Ono","year":"2003","journal-title":"Chest"},{"issue":"18","key":"10.1002\/14651858.CD002994.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehi283","article-title":"Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension","volume":"26","author":"Opitz","year":"2005","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD002994.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1378\/chest.117.1.14","article-title":"Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus","volume":"117","author":"Robbins","year":"2000","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD002994.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1378\/chest.127.5.1870","article-title":"Epoprostenol and nesiritide in pulmonary hypertension","volume":"127","author":"Rubin","year":"2005","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00005344-199803000-00006","article-title":"Long-term effects of cicletanine on secondary pulmonary hypertension","volume":"31","author":"Saadjian","year":"1998","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD002994.pub2-BIB0070|cit70","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study","volume":"19","author":"Scorza","year":"2001","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD002994.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0735-1097(97)00187-3","article-title":"Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion","volume":"30","author":"Shapiro","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD002994.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1378\/chest.123.4.1293","article-title":"Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension","volume":"123","author":"Stiebellehner","year":"2003","journal-title":"Chest"},{"issue":"24","key":"10.1002\/14651858.CD002994.pub2-BIB0073|cit73","first-page":"923","article-title":"Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension","volume":"129","author":"Stricker","year":"1999","journal-title":"Schweizerische Medizinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD002994.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/heart.86.6.661","article-title":"Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue","volume":"86","author":"Vizza","year":"2001","journal-title":"Heart"},{"issue":"2","key":"10.1002\/14651858.CD002994.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"149","DOI":"10.7326\/0003-4819-144-2-200601170-00026","article-title":"Inhaled trepostinil for treatment of chronic pulmonary arterial hypertension","volume":"144","author":"Voswinckel","year":"2006","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/hc3601.096826","article-title":"Effect of inhaled Iloprost plus oral sildenafil in patients with primary pulmonary hypertension","author":"Wilkens","year":"2001","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD002994.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s10096-003-1024-1","article-title":"Micrococcus infection in patients receiving epoprostenol by continuous infusion","volume":"22","author":"Yap","year":"2003","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002994.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"35s","DOI":"10.1378\/chest.126.1_suppl.35S","article-title":"Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","volume":"126","author":"Badesch","year":"2004","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0080|cit80","first-page":"80","article-title":"Bias","volume":"October","author":"Bandolier","year":"2000","journal-title":"Bandolier"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1136\/hrt.47.5.511","article-title":"Failure of nifedipine treatment in primary pulmonary hypertension","volume":"47","author":"Berkenboom","year":"1982","journal-title":"British Heart Journal"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0082|cit82","unstructured":"Black C Personal communication 2001"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0083|cit83","first-page":"353","article-title":"Pulmonary hypertension in collagen vascular disease","volume-title":"The Pulmonary Circulation","author":"Brundage","year":"1990"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002994.pub2-BIB0085|cit85","first-page":"380","article-title":"Noninvasive assessment of haemodynamic improvement during chronic vasodilator therapy in obliterative pulmonary hypertension","volume":"133","author":"D'Alonzo","year":"1986","journal-title":"American Review of Respiratory Disease"},{"issue":"5","key":"10.1002\/14651858.CD002994.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with PPH. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002994.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1378\/chest.83.4.708","article-title":"Fatal outcome following nifedipine for pulmonary hypertension","volume":"83","author":"Farber","year":"1983","journal-title":"Chest"},{"issue":"11","key":"10.1002\/14651858.CD002994.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/art.1780241111","article-title":"Abnormalities of pulmonary vascular dynamics and inflammation in early progressive systemic sclerosis","volume":"24","author":"Furst","year":"1981","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2165\/00003495-199243060-00008","article-title":"Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures","volume":"43","author":"Grant","year":"1992","journal-title":"Drugs"},{"issue":"3","key":"10.1002\/14651858.CD002994.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1164\/ajrccm\/136.3.782","article-title":"The place of prostacyclin in the clinical management of primary pulmonary hypertension","volume":"136","author":"Higenbottam","year":"1987","journal-title":"American Review of Respiratory Disease"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/hrt.70.4.366","article-title":"Prostacyclin (epoprostenol) heart-lung transplantation as treatments for severe pulmonary hypertension","volume":"70","author":"Higenbottam","year":"1993","journal-title":"British Heart Journal"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0092|cit92","first-page":"3","article-title":"Prostacyclin","volume":"14","author":"Higenbottam","year":"1995","journal-title":"Bandolier"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1183\/09031936.99.13613579","article-title":"Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study","volume":"13","author":"Humbert","year":"1999","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomised controlled trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD002994.pub2-BIB0095|cit95","article-title":"Sildenafil for pulmonary hypertension (Cochrane review)","author":"Kanthapillai","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD002994.pub2-BIB0096|cit96","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004434.pub2","article-title":"Endothelin receptor antagonists for pulmonary arterial hypertension (Cochrane review)","author":"Liu","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJM199207093270209","article-title":"Endothelial dysfunction in pulmonary hypertension","volume":"327","author":"Loscalzo","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/263663a0","article-title":"An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibts platelet aggregation","volume":"263","author":"Moncada","year":"1976","journal-title":"Nature"},{"issue":"1","key":"10.1002\/14651858.CD002994.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1378\/chest.113.1.237","article-title":"Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease","volume":"113","author":"Palmer","year":"1988","journal-title":"Chest"},{"issue":"2","key":"10.1002\/14651858.CD002994.pub2-BIB0100|cit100","article-title":"Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis (Cochrane review)","author":"Pope","year":"2001","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/01.CIR.76.1.135","article-title":"High dose channel blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy","volume":"76","author":"Rich","year":"1987","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD002994.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1378\/chest.81.3.357","article-title":"Some basic and clinical challenges in the pulmonary circulation","volume":"81","author":"Robin","year":"1982","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJM199701093360207","article-title":"Primary pulmonary hypertension","volume":"336","author":"Rubin","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-86-4-394","article-title":"Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma)","volume":"86","author":"Salerni","year":"1977","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/art.1780290409","article-title":"Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis","volume":"29","author":"Stupi","year":"1986","journal-title":"Arthritis Rheumatism"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0002-9343(83)91169-5","article-title":"Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis","volume":"75","author":"Ungerer","year":"1983","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD002994.pub2-BIB0107|cit107","first-page":"137","article-title":"Lung disease in association with connective tissue diseases","volume":"14","author":"Wells","year":"2000","journal-title":"European Respiratory Monograph"},{"issue":"5","key":"10.1002\/14651858.CD002994.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/0046-8177(90)90002-M","article-title":"The pulmonary pathologic manifestations of the CREST syndrome","volume":"21","author":"Yousem","year":"1990","journal-title":"Human Pathology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD002994.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:14:43Z","timestamp":1628543683000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002994.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2005,4,20]]},"references-count":108,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002994.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,20]]}}}